Effect of Fructose and 3,5-Diiodothyronine (3,5-T₂) on Lipid Accumulation and Insulin Signalling in Non-Alcoholic Fatty Liver Disease (NAFLD)-Like Rat Primary Hepatocytes

Abstract

Non-alcoholic fatty liver disease (NAFLD) is nowadays considered as one of the most serious pathological conditions affecting the liver. NAFLD is supposed to be initiated by the accumulation of lipids in the liver, which finally results in an impaired hepatic insulin signalling. Many researchers have recently focused their attention on the role played by fructose as a NAFLD-triggering agent, because of the increased diffusion of fructose-sweetened food. However, epidemiological data do not permit to evaluate the role of fructose per se, because these foods are often associated with elevated energy intake and unhealthy lifestyle. In the present work, we analysed the effects of fructose on the accumulation of lipids and insulin signalling in rat primary hepatocytes. Moreover, we investigated the effect of the thyroid hormone metabolite, devoid of thyrotoxic effects, 3,5-diiodothyronine (3,5-T₂) over the same parameters. To evaluate the effect on insulin signalling we took into consideration three key proteins, such as p85 subunit of phosphatidylinositol 3-kinase (PI3K), phosphatase and tensin homolog (PTEN), and Akt. Our results show that fructose in vitro, in the range of physiological concentrations, was not able to stimulate either lipid accumulation or to impair insulin signalling in our NAFLD-like rat primary hepatocytes. Our data thus support the idea that fructose per se may exert detrimental effects mainly triggering systemic effects, rather than directly affecting isolated hepatocytes. Moreover, we demonstrated that 3,5-T₂, at physiological levels, reduces lipid content and triggers phosphorylation of Akt in an insulin receptor-independent manner, revealing new interesting properties as a biologically active molecule.

Key words

insulin signal transduction - Akt - p85 - PTEN

• References

• 1 Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-161
• 2 White JS. Straight talk about high-fructose corn syrup: what it is and what it ain’t. Am J Clin Nutr 2008; 88: 1716S-1721S
• 3 Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011; 1364: 2392-2404
• 4 Day CP, James OFW. Steatohepatitis: a tale of two “hits”?. Gastroenterology 1998; 114: 842-845
• 5 Samuel VT, Shulman GI. Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell 2012; 148: 852-871
• 6 Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, Kahn CR. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 2002; 109: 141-149
• 7 Shen YH, Zhang L, Gan Y, Wang X, Wang J, LeMaire SA, Coselli JS, Wang XL. Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signalling. A cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells. J Biol Chem 2006; 281: 7727-7736
• 8 Liu HY, Collins QF, Xiong Y, Moukdar F, Lupo Jr EG, Liu Z, Cao W. Prolonged treatment of primary hepatocytes with oleate induces insulin resistance through p38 mitogen-activated protein kinase. J Biol Chem 2007; 282: 14205-14212
• 9 Lee SK, Lee JO, Kim JH, Kim SJ, You GY, Moon JW, Jung JH, Park SH, Uhm KO, Park JM, Suh PG, Kim HS. Metformin sensitizes insulin signaling through AMPK-mediated PTEN down-regulation in preadipocyte 3T3-L1 cells. J Cell Biochem 2011; 112: 1259-1267
• 10 Arnold S, Goglia F, Kadenbach B. 3,5-diiodothyronine binds to subunit Va of cytochrome c oxidase and abolishes the allosteric inhibition of respiration by ATP. Eur J Biochem 1998; 252: 325-330
• 11 Lombardi A, Beneduce L, Moreno M, Diano S, Colantuoni V, Ursini MV, Lanni A, Goglia F. 3,5-Diiodo-l-Thyronine Regulates Glucose-6-Phosphate Dehydrogenase Activity in the Rat. Endocrinology 2000; 141: 1729-1734
• 12 Cavallo A, Priore P, Gnoni GV, Papa S, Zanotti F, Gnoni A. 3,5-Diiodo-l-thyronine administration to hypothyroid rats rapidly enhances fatty acid oxidation rate and bioenergetic parameters in liver cells. PLoS ONE 2013; 8: e52328
• 13 Mollica MP, Lionetti L, Moreno M, Lombardi A, De Lange P, Antonelli A, Lanni A, Cavaliere G, Barletta A, Goglia F. 3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. J Hepatol 2009; 51: 363-370
• 14 Yen PM. Physiological and Molecular Basis of Thyroid Hormone Action. Physiol Rev 2001; 81: 1097-1142
• 15 Ball SG, Sokolov J, Chin WW. 3,5-Diiodo-l-thyronine (T₂) has selective thyromimetic effects in vivo and in vitro. J Mol Endocrinol 1997; 19: 137-1472
• 16 Vidyashankar S, Sandeep Varma R, Patki PS. Quercetin ameliorates insulin resistance and up-regulates cellular antioxidants during oleic acid induced hepatic steatosis in HepG2 cells. Toxicol In Vitro 2013; 27: 945-953
• 17 Moldeus P, Högberg J, Orrenius S. Isolation and use of liver cells. Methods Enzymol 1978; 52: 60-71
• 18 De Colli M, Massimi M, Barbetta A, Di Rosario BL, Nardecchia S, Conti Devirgiliis L, Dentini M. A biomimetic porous hydrogel of gelatin and glycosaminoglycans cross-linked with transglutaminase and its application in the culture of hepatocytes. Biomed Mater 2012; 7: 055005
• 19 Koopman R, Schaart G, Hesselink MK. Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids. Histochem Cell Biol 2001; 116: 63-68
• 20 Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 2008; 3: 1125-1131
• 21 Ohkawa H, Ohishi N, Yagi K. Assay for Lipid Peroxides in Animal Tissues by Thiobarbituric Acid Reaction. Anal Biochem 1979; 95: 351-358
• 22 Bucio L, Souza V, Albores A, Sierra A, Chávez E, Cárabez A, Gutierrérrez-Ruiz MC. Cadmium and mercury toxicity in a human fetal hepatic cell line (WRL-68 cells). Toxicology 1995; 102: 285-299
• 23 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
• 24 Peterson GL. Review of the Folin Phenol Protein Quantitation Method of Lowry, Rosebrough, Farr, and Randall. Anal Biochem 1979; 100: 201-220
• 25 Segal MS, Gollub E, Johnson RJ. Is the fructose index more relevant with regards to cardiovascular disease than the glycemic index?. Eur J Nutr 2007; 46: 406-417
• 26 Wiersinga WM, Chopra IJ. Radioimmunoassay of thyroxine (T₄), 3,5,3′-triiodothyronine (T₃), 3,3′,5′-triiodothyronine (reverse T₃, rT₃), and 3,3′-diiodothyronine (T₂). Methods Enzymol 1982; 84: 272-303
• 27 Pinna G, Meinhold H, Hiedra L, Thoma R, Hoell T, Gräf KJ, Stoltenburg-Didinger G, Eravci M, Prengel H, Brödel O, Finke R, Baumgartner A. Elevated 3,5-Diiodothyronine Concentrations in the Sera of Patients with Nonthyroidal Illnesses and Brain Tumors. J Clin Endocrinol Metab 1997; 82: 1535-1542
• 28 Moreno M, Lombardi A, Beneduce L, Silvestri E, Pinna G, Goglia F, Lanni A. Are the effects of T₃ on Resting Metabolic Rate in Euthyroid Rats Entirely Caused by T₃ itself?. Endocrinology 2002; 143: 504-510
• 29 Sievenpiper JL, de Souza RJ, Mirrahimi A, Yu ME, Carleton AJ, Beyene J, Chiavaroli L, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Kendall CW, Jenkins D. Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. Ann Intern Med 2012; 156: 291-304
• 30 Lê KA, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, Boesch C, Tappy L. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr 2009; 89: 1760-1765
• 31 Huang D, Dhawan T, Young S, Yong WH, Boros LG, Heaney AP. Fructose impairs glucose-induced hepatic triglyceride synthesis. Lipids Health Dis 2011; 10: 20
• 32 Li P, Koike T, Qin B, Kubota M, Kawata Y, Jia YJ, Oshida Y. A High-fructose Diet Impairs Akt and PKCζ Phosphorylation and GLUT4 Translocation in Rat Skeletal Muscle. Horm Metab Res 2008; 40: 528-532
• 33 Kanuri G, Spruss A, Wagnerberger S, Bischoff SC, Bergheim I. Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 2011; 22: 527-534
• 34 Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009; 50: 1094-1104
• 35 Alisi A, Pastore A, Ceccarelli S, Panera N, Gnani D, Bruscalupi G, Massimi M, Tozzi G, Piemonte F, Nobili V. Emodin prevents intrahepatic fat accumulation, inflammation and redox status imbalance during diet-induced hepatosteatosis in rats. Int J Mol Sci 2012; 13: 2276-2289
• 36 Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, Woods SC, Seeley RJ. High-fructose medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010; 52: 934-944
• 37 Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 2002; 22: 965-977
• 38 Grasselli E, Voci A, Canesi L, De Matteis R, Goglia F, Cioffi F, Fugassa E, Gallo G, Vergani L. Direct effects of iodothyronines on excess fat storage in rat hepatocytes. J Hepatol 2011; 54: 1230-1236
• 39 Incerpi S, De Vito P, Luly P, Spagnuolo S, Leoni S. Short term effects of thyroid hormones and 3,5-diiodothyronine on membrane transport systems in chick embryo hepatocytes. Endocrinology 2002; 143: 1660-1668
• 40 Rochira A, Damiano F, Marsigliante S, Gnoni GV, Siculella L. 3,5-Diiodo-L-thyronine induces SREBP-1 proteolytic cleavage block and apoptosis in human hepatoma (Hepg2) cells. Biochim Biophys Acta 2013; 1831: 1679-1689
• 41 de Lange P, Cioffi F, Senese R, Moreno M, Lombardi A, Silvestri E, De Matteis R, Lionetti L, Mollica MP, Goglia F, Lanni A. Nonthyrotoxic Prevention of Diet-Induced Insulin Resistance by 3,5-Diiodo-l-Thyronine in Rats. Diabetes 2011; 60: 2730-2739
• 42 Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev 2010; 31: 139-170
• 43 Scapin S, Leoni S, Spagnuolo S, Gnocchi D, De Vito P, Luly P, Pedersen JZ, Incerpi S. Short-term effects of thyroid hormones during development: Focus on signal transduction. Steroids 2010; 75: 576-584
• 44 Gnocchi D, Leoni S, Incerpi S, Bruscalupi G. 3,5,3′-triiodothyronine (T3) stimulates cell proliferation through the activation of the PI3K/Akt pathway and reactive oxygen species (ROS) production in chick embryo hepatocytes. Steroids 2012; 77: 589-595
• 45 Moeller LC, Cao X, Dumitrescu AM, Seo H, Refetoff S. Thyroid hormone mediated changes in gene expression can be initiated by cytosolic action of the thyroid hormone receptor beta through the phosphatidylinositol 3-kinase pathway. Nucl Recept Signal 2006; 4: e020
• 46 Grasselli E, Voci A, Canesi L, Goglia F, Ravera S, Panfoli I, Gallo G, Vergani L. Non-receptor-mediated actions are responsible for the lipid-lowering effects of iodothyronines in FaO rat hepatoma cells. J Endocrinol 2011; 210: 59-69
• 47 Moreno M, Silvestri E, Lombardi A, Visser TJ, Goglia F, Lanni A. Identification of 3,5-Diiodo-l-Thyronine-Binding Proteins in Rat Liver Cytosol by Photoaffinity Labeling. Endocrinology 2003; 144: 2297-2203
• 48 Vatner DF, Weismann D, Beddow SA, Kumashiro N, Erion DM, Liao XH, Grover GJ, Webb P, Phillips KJ, Weiss RE, Bogan JS, Baxter J, Shulman GI, Samuel VT. Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. Am J Physiol Endocrinol Metab 2013; 305: E89-E100
• 49 Mousa SA, O’Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ. The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol 2005; 46: 356-360